Management Changes at NanoEcho: Linda Persson is stepping down from her role as CEO and will remain available to the company during a transition period. Chairman of the Board Björn Larsson assumes the position of interim CEO with immediate effect and will hold this role until a permanent CEO is appointed. #biotech #medtech #management #investing
Biostock
@biostock
- 1 Followers
- 1 Following
- 76 Posts
BioStock is a digital news and analysis service, based in Sweden, focused on the Nordic Life Science sector.
Iconovo and Lonza Enter LOI for Strategic Partnership
Iconovo and Lonza have signed a Letter of Intent to establish a long-term collaboration focused on inhalable biologics. This agreement aims to secure their respective positions in the biological medicines sector. Jan Vertommen, VP at Lonza, confirmed the company's interest in inhalable therapies and the intent to expand cooperation with Iconovo.
Paxman Announces CPT Codes for CIPN
Paxman announces Category III CPT codes for cryocompression therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). This establishes a formal coding structure for the US market introduction. The three-code system mirrors the framework for the company's FDA-cleared scalp cooling, supporting data collection and payer engagement.
FDA Clears FluoGuide's IND for FG001
FluoGuide has obtained FDA clearance for its Investigational New Drug (IND) application regarding FG001 in high-grade glioma. This regulatory step transitions the asset into late-clinical development towards U.S. registration. The company also confirmed FDA alignment on the U.S. Phase II trial design and key elements of the subsequent Phase III program.
Coegin Pharma Executes Directed Issues
The company has carried out directed issues totaling approximately SEK 12 million. The subscription price is set at SEK 3.25 per share. This corresponds to a discount of approximately 15 percent compared to the volume-weighted average price (VWAP) of the company share during the preceding ten trading days.
iZafe Group Resolves on Directed Share Issues
The Board has approved two directed issues totaling 60,104,987 B-shares at a subscription price of SEK 0.33 per share. The first tranche (20,868,973 shares) utilizes the AGM mandate. The second tranche (39,236,014 shares) requires approval at an EGM planned for March 12, 2026.
Nexstim receives EU MDR certification for NBS 6 system
Nexstim has secured EU MDR certification for its NBS 6 system. This authorizes marketing for treating surgically induced post-operative motor deficits of the upper limb. The system serves as an adjunct therapy for motor rehabilitation in adult patients following brain tumor surgery. This adds to existing certifications for pre-surgical mapping, depression, and pain treatment.
Oncopeptides Announces Rights Issue
Oncopeptides executes a rights issue of approx SEK 200 million. Proceeds will support Pepaxti commercialization in Europe and advance the glioblastoma project to clinical development, including a window-of-opportunity study. HealthCap VIII LP commits SEK 20 million.
Magle Group Issues Profit Warning
Magle Group announces a profit warning ahead of Q4 results. Following a strategic refocus in January 2026, Q4 2025 EBITDA is estimated at approximately negative SEK 42 million, down from SEK 20 million in 2024. The result reflects restructuring costs, impairments, and asset write-downs aligned with the company's commitment to operational discipline.
Synartro Reports LPLV in Phase I/IIa Study
Synartro announces the last participant's last visit in the Phase I/IIa clinical trial of SYN321, an intra-articular treatment for knee osteoarthritis. Initiated in August 2025, the study involved 35 participants across four cohorts to evaluate safety, tolerability, PK, and early efficacy.